Best Biotech Stocks to Buy Now (2024)Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.
Industry: Biotechnology
| Ticker | Company | Country | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|
| INCY | INCYTE CORP | United States | $11.60B | 224,526,128 | 79.30% | 20.70% | Net Selling | Net Buying |
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | United States | $1.64B | 56,769,081 | 61.03% | 38.97% | Net Selling | Net Selling |
| VYGR | VOYAGER THERAPEUTICS INC | United States | $415.40M | 54,300,627 | 47.14% | 52.86% | Net Selling | Net Selling |
| AMLX | AMYLYX PHARMACEUTICALS INC | United States | $132.18M | 67,782,139 | 52.42% | 47.58% | Net Buying | Net Selling |
| UTHR | UNITED THERAPEUTICS CORP | United States | $11.03B | 47,058,545 | 87.59% | 12.41% | Net Selling | Net Selling |
| CORT | CORCEPT THERAPEUTICS INC | United States | $2.38B | 103,517,388 | 30.65% | 69.35% | Net Buying | Net Buying |
| EXEL | EXELIXIS INC | United States | $7.06B | 303,194,259 | 85.28% | 4.07% | Net Selling | Net Buying |
| PBYI | PUMA BIOTECHNOLOGY INC | United States | $247.30M | 48,207,162 | 55.20% | 44.43% | Net Selling | |
| HALO | HALOZYME THERAPEUTICS INC | United States | $4.94B | 126,824,800 | 78.23% | 21.77% | Net Selling | Net Selling |
| MDXG | MIMEDX GROUP INC | United States | $956.70M | 146,958,420 | 42.42% | 57.58% | Net Buying | Net Selling |
| RPRX | ROYALTY PHARMA PLC | United States | $16.62B | 597,434,791 | 51.02% | 16.51% | Net Selling | Net Buying |
| ROIV | ROIVANT SCIENCES LTD | Bermuda | $8.82B | 805,846,006 | 40.14% | 59.86% | Net Selling | Net Selling |
| TGTX | TG THERAPEUTICS INC | United States | $2.20B | 154,420,772 | 53.78% | 46.22% | Net Selling | Net Selling |
| GMAB | GENMAB A | Denmark | $18.87B | 66,074,535 | 70.53% | 0.00% | ||
| MEIP | MEI PHARMA INC | United States | $22.20M | 6,662,857 | 17.91% | 82.09% | Net Buying | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | United States | $17.37B | 188,675,622 | 98.08% | 1.63% | Net Selling | Net Selling |
| BNTX | BIONTECH SE | Germany | $21.04B | 237,725,735 | 17.05% | 0.00% | ||
| VNDA | VANDA PHARMACEUTICALS INC | United States | $266.40M | 57,537,499 | 56.23% | 43.77% | Net Selling | Net Selling |
| PLX | PROTALIX BIOTHERAPEUTICS INC | Israel | $87.66M | 73,052,124 | 6.75% | 93.25% | Net Buying | |
| DBVT | DBV TECHNOLOGIES SA | France | $131.15M | 96,431,770 | 39.10% | 15.37% | Net Buying | Net Buying |
| AVRO | AVROBIO INC | United States | $54.28M | 44,860,515 | 46.76% | 53.24% | Net Selling | Net Selling |
| SPRO | SPERO THERAPEUTICS INC | United States | $77.30M | 53,869,139 | 25.60% | 64.13% | Net Selling | Net Selling |
| BNOX | BIONOMICS LIMITED | Australia | $10.66M | 1,924,808,444 | 0.07% | 0.00% | ||
| CRSP | CRISPR THERAPEUTICS AG | Switzerland | $4.53B | 80,275,950 | 62.44% | 37.56% | Net Buying | Net Buying |
| KRYS | KRYSTAL BIOTECH INC | United States | $4.58B | 28,292,616 | 75.55% | 24.45% | Net Selling | Net Selling |
| CPRX | CATALYST PHARMACEUTICALS INC | United States | $1.74B | 117,863,258 | 71.64% | 16.33% | Net Buying | Net Buying |
| SEER | SEER INC | United States | $117.24M | 64,773,180 | 54.70% | 45.30% | Net Buying | Net Selling |
| IGMS | IGM BIOSCIENCES INC | United States | $452.66M | 58,786,588 | 37.27% | 54.48% | Net Buying | Net Buying |
| OCUP | OCUPHIRE PHARMA INC | United States | $38.21M | 24,813,370 | 1.23% | 98.77% | Net Buying | Net Buying |
| KNSA | KINIKSA PHARMACEUTICALS LTD | Bermuda | $1.25B | 70,615,022 | 48.48% | 9.87% | Net Selling | Net Selling |
| TFFP | TFF PHARMACEUTICALS INC | United States | $7.48M | 2,519,220 | 3.17% | 96.83% | Net Buying | |
| NVO | NOVO NORDISK A S | Denmark | $580.17B | 4,510,000,000 | 6.84% | 0.00% | ||
| ADAG | ADAGENE INC | China | $116.91M | 55,145,839 | 12.92% | 0.00% | ||
| AXSM | AXSOME THERAPEUTICS INC | United States | $3.46B | 47,374,375 | 71.00% | 29.00% | Net Selling | Net Buying |
| MIRM | MIRUM PHARMACEUTICALS INC | United States | $1.15B | 47,003,329 | 48.94% | 51.06% | Net Buying | Net Selling |
| REGN | REGENERON PHARMACEUTICALS INC | United States | $99.59B | 109,761,896 | 69.39% | 30.61% | Net Selling | Net Buying |
| FULC | FULCRUM THERAPEUTICS INC | United States | $460.80M | 61,935,171 | 64.02% | 35.98% | Net Buying | Net Buying |
| IDYA | IDEAYA BIOSCIENCES INC | United States | $2.91B | 74,560,273 | 88.70% | 10.03% | Net Selling | Net Selling |
| VYNE | VYNE THERAPEUTICS INC | United States | $32.71M | 14,098,888 | 23.19% | 76.81% | Net Buying | Net Selling |
| CLGN | COLLPLANT BIOTECHNOLOGIES LTD | Israel | $61.84M | 11,452,672 | 12.49% | 0.00% | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | Ireland | $6.84B | 62,345,283 | 26.94% | 73.06% | Net Selling | Net Selling |
| VTGN | VISTAGEN THERAPEUTICS INC | United States | $130.53M | 27,025,209 | 38.92% | 61.08% | Net Buying | |
| IMMP | IMMUTEP LTD | Australia | $298.40M | 1,188,834,559 | 0.17% | 0.00% | ||
| AGIO | AGIOS PHARMACEUTICALS INC | United States | $1.79B | 56,194,847 | 75.09% | 24.91% | Net Selling | Net Selling |
| RNA | AVIDITY BIOSCIENCES INC | United States | $2.00B | 79,719,473 | 82.47% | 17.53% | Net Selling | Net Selling |
| PRTA | PROTHENA CORP PUBLIC LTD CO | Ireland | $1.10B | 53,720,455 | 53.06% | 46.94% | Net Buying | |
| TECH | BIO-TECHNE CORP | United States | $10.01B | 157,191,685 | 97.66% | 2.34% | Net Buying | Net Selling |
| MDWD | MEDIWOUND LTD | Israel | $151.33M | 9,221,764 | 27.28% | 0.00% | ||
| INM | INMED PHARMACEUTICALS INC | Canada | $1.65M | 6,056,970 | 13.28% | 11.17% | Net Buying | Net Buying |
| GNFT | GENFIT SA | France | $171.68M | 49,834,983 | 1.27% | 0.00% | ||
| ALGS | ALIGOS THERAPEUTICS INC | United States | $62.35M | 75,668,521 | 54.25% | 45.75% | Net Buying | |
| ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | United States | $751.74M | 26,915,243 | 87.10% | 12.90% | Net Selling | Net Selling |
| KZR | KEZAR LIFE SCIENCES INC | United States | $60.13M | 72,801,359 | 67.83% | 21.82% | Net Buying | |
| LPCN | LIPOCINE INC | United States | $25.52M | 5,315,830 | 5.77% | 94.23% | Net Buying | |
| ANIX | ANIXA BIOSCIENCES INC | United States | $97.93M | 31,899,800 | 13.83% | 84.70% | Net Buying | Net Buying |
| LEGN | LEGEND BIOTECH CORP | United States | $8.63B | 363,822,069 | 23.61% | 0.00% | ||
| PTGX | PROTAGONIST THERAPEUTICS INC | United States | $1.56B | 58,274,998 | 79.94% | 20.06% | Net Selling | Net Selling |
| LIFE | ATYR PHARMA INC | United States | $109.76M | 67,750,024 | 60.86% | 22.55% | Net Buying | Net Selling |
| ZLAB | ZAI LAB LTD | China | $1.50B | 992,087,430 | 4.15% | 1.96% | Net Buying | Net Buying |
| SAGE | SAGE THERAPEUTICS INC | United States | $778.38M | 60,106,687 | 71.61% | 28.39% | Net Selling | |
| GLPG | GALAPAGOS NV | Belgium | $1.94B | 65,897,071 | 30.01% | 0.00% | ||
| MORF | MORPHIC HOLDING INC | United States | $1.44B | 50,037,229 | 64.32% | 35.68% | Net Buying | Net Buying |
| QURE | UNIQURE NV | Netherlands | $227.23M | 47,838,275 | 78.37% | 13.99% | Net Selling | Net Selling |
| XCUR | EXICURE INC | United States | $4.67M | 8,648,307 | 0.89% | 99.11% | Net Selling | Net Selling |
| GBIO | GENERATION BIO CO | United States | $216.72M | 66,477,111 | 63.23% | 36.77% | Net Buying | Net Selling |
| ORMP | ORAMED PHARMACEUTICALS INC | United States | $95.22M | 40,519,160 | 12.73% | 46.50% | ||
| NRBO | NEUROBO PHARMACEUTICALS INC | United States | $14.82M | 4,906,032 | 0.25% | 99.75% | ||
| ACIU | AC IMMUNE SA | Switzerland | $236.09M | 99,197,829 | 29.88% | 0.00% | ||
| SLGL | SOL-GEL TECHNOLOGIES LTD | Israel | $25.77M | 27,857,620 | 28.59% | 0.00% | ||
| ABIO | ARCA BIOPHARMA INC | United States | $52.93M | 14,501,143 | 4.98% | 95.02% | ||
| SNSE | SENSEI BIOTHERAPEUTICS INC | United States | $25.02M | 25,070,980 | 11.82% | 71.99% | Net Selling | Net Selling |
| ARGX | ARGENX SE | Belgium | $22.20B | 59,194,488 | 55.29% | 0.00% | ||
| XBIO | XENETIC BIOSCIENCES INC | United States | $5.93M | 1,540,684 | 0.42% | 99.58% | ||
| BOLT | BOLT BIOTHERAPEUTICS INC | United States | $42.32M | 38,127,740 | 54.74% | 45.26% | Net Selling | |
| FATE | FATE THERAPEUTICS INC | United States | $450.54M | 99,237,508 | 61.86% | 38.14% | Net Selling | Net Selling |
| FUSN | FUSION PHARMACEUTICALS INC | Canada | $1.81B | 84,692,585 | 71.20% | 28.80% | ||
| MRUS | MERUS NV | Netherlands | $2.36B | 57,878,284 | 87.00% | 13.00% | Net Selling | |
| VERV | VERVE THERAPEUTICS INC | United States | $575.30M | 83,619,279 | 62.25% | 37.75% | Net Buying | Net Selling |
| BCYC | BICYCLE THERAPEUTICS PLC | United Kingdom | $965.85M | 42,586,185 | 54.60% | 45.40% | Net Selling | Net Selling |
| TRAW | TRAWS PHARMA INC | United States | $13.99M | 21,040,645 | 5.95% | 94.05% | Net Selling | Net Selling |
| ZVRA | ZEVRA THERAPEUTICS INC | United States | $198.89M | 43,426,186 | 29.20% | 27.84% | Net Buying | |
| CLNN | CLENE INC | United States | $43.02M | 128,430,098 | 9.06% | 52.75% | Net Buying | Net Selling |
| MRKR | MARKER THERAPEUTICS INC | United States | $39.40M | 8,902,897 | 1.30% | 98.70% | ||
| EDIT | EDITAS MEDICINE INC | United States | $446.70M | 81,813,850 | 64.04% | 35.96% | Net Selling | Net Selling |
| JANX | JANUX THERAPEUTICS INC | United States | $2.57B | 51,660,060 | 54.14% | 45.86% | Net Buying | |
| PLUR | PLURI INC | Israel | $25.93M | 5,185,022 | 0.58% | 99.42% | ||
| ALT | ALTIMMUNE INC | United States | $536.68M | 70,895,286 | 34.70% | 65.30% | Net Selling | Net Selling |
| SPRY | ARS PHARMACEUTICALS INC | United States | $820.26M | 96,501,554 | 43.74% | 56.26% | Net Buying | Net Buying |
| SPRB | SPRUCE BIOSCIENCES INC | United States | $28.85M | 41,149,160 | 63.59% | 36.41% | Net Selling | Net Selling |
| RYTM | RHYTHM PHARMACEUTICALS INC | United States | $2.41B | 60,140,495 | 87.96% | 12.04% | Net Selling | Net Selling |
| RVMD | REVOLUTION MEDICINES INC | United States | $5.97B | 164,690,408 | 89.46% | 10.54% | Net Selling | Net Selling |
| BGNE | BEIGENE LTD | Cayman Islands | $14.55B | 1,359,513,224 | 3.31% | 34.70% | Net Selling | Net Selling |
| VRTX | VERTEX PHARMACEUTICALS INC | United States | $104.59B | 258,307,816 | 90.91% | 1.48% | Net Selling | Net Selling |
| EYPT | EYEPOINT PHARMACEUTICALS INC | United States | $875.53M | 49,830,792 | 20.11% | 79.89% | Net Selling | Net Buying |
| CDIO | CARDIO DIAGNOSTICS HOLDINGS INC | United States | $16.21M | 21,591,119 | 7.67% | 34.34% | Net Buying | Net Buying |
| ITOS | ITEOS THERAPEUTICS INC | United States | $393.92M | 35,843,131 | 62.37% | 37.63% | Net Selling | |
| SRPT | SAREPTA THERAPEUTICS INC | United States | $10.99B | 93,855,410 | 73.88% | 26.12% | Net Buying | Net Selling |
| PLRX | PLIANT THERAPEUTICS INC | United States | $754.19M | 60,239,176 | 70.74% | 29.26% | Net Selling | |
| BRNS | BARINTHUS BIOTHERAPEUTICS PLC | United Kingdom | $99.25M | 38,921,212 | 24.97% | 54.37% | Net Buying | |
| ARDX | ARDELYX INC | United States | $1.49B | 232,686,008 | 38.01% | 61.99% | Net Selling | Net Selling |
Biotech Stocks FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.